Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Achieving “Progress” in Progressive Multiple Sclerosis: Advances in Therapy
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: November 15, 2021 Expiration: November 14, 2022
Start Activity
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme
Daniel Kantor, MD, FAAN
Program Director
person default
Shirley Nedzesky

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the characteristics of progressive forms of MS, including transition from relapsing to active secondary progressive MS
  • Evaluate the evidence-based safety, efficacy and tolerability of available and investigational DMTs for the management of progressive forms of MS
  • Collaborate with patients on appropriate patient-specific management strategies, including education and access to services

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Daniel Kantor, MD, FAAN

President Emeritus
Florida Society of Neurology
Florida Atlantic University
Nova Southeastern University
Florida

Daniel Kantor, MD, reports consulting fees from Bristol Myers Squibb, Janssen Pharmaceuticals, and Sandoz, and reports fees for non-CME services from Bristol Myers Squibb and Janssen Pharmaceuticals.

Faculty

Shirley Nedzesky

Patient

Shirley Nedzesky has no relevant conflicts of interest to report.

Staff

Susan Daniels, PhD
Scientific Director
Susan Daniels, PhD, has no relevant conflicts of interest to report.
Ruth Cohen
Ruth Cohen has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Mary Knudtson, DNSc, NP, FAAN
Associate Vice Chancellor
Student Health and Wellness
Executive Director
Student Health Services
University of California, Santa Cruz
Santa Cruz, California
Professor of Clinical Nursing
University of California, Irvine
Irvine Irvine, California

 

Mary Knudtson, DNSc, NP, FAAN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended neurology, internal medicine, and primary care physicians; nurse practitioners; nurses; and other healthcare providers who manage patients with MS.

Goal

The goal of the education is to increase clinicians’ knowledge, competence, and application of the recognition of and diagnostic criteria for PPMS and SPMS, including acknowledgement of the patient experience in living with progressive disease; the latest authoritative guidelines for the management of progressive MS phenotypes; and the safety, efficacy, and tolerability profiles of currently available and investigational therapies for PPMS and SPMS.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.50 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 15, 2021, through November 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Achieving “Progress” in Progressive Multiple Sclerosis: Advances in Therapy
  • CME
  • CE

Loading...
A faculty expert and a patient with MS provide their insights on therapies for progressive MS and management of symptoms. Download the slideset and complete the interactive Medical Minute activity.
Daniel Kantor, MD, FAAN
Program Director
person default
Shirley Nedzesky
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: November 15, 2021 Expiration: November 14, 2022

Related Content

Clinical Care Options (CCO) downloadable slideset of faculty expert and a patient with MS discussing therapies for progressive MS and management of MS symptoms

Daniel Kantor, MD, FAAN
Program Director
person default Shirley Nedzesky
Released: November 15, 2021

Calli Cook, DNP, APRN, FNP-C, FAANP and Lisa Aquillano, PharmD, BCPS, MSCS: Important considerations when starting or stopping disease modifying therapies in patients with MS are discussed.

person default Lisa Aquillano, PharmD, BCPS, MSCS person default Calli Cook, DNP, APRN, FNP-C, FAANP Nurse Practitioners: 0.67 AANP contact hours Released: August 1, 2020 Expired: No longer available for credit

Calli Cook, DNP, APRN, FNP-C, FAANP and Lisa Aquillano, PharmD, BCPS, MSCS: Important considerations when starting or stopping disease modifying therapies in patients with MS.

person default Lisa Aquillano, PharmD, BCPS, MSCS person default Calli Cook, DNP, APRN, FNP-C, FAANP Nurse Practitioners: 0.5 AANP contact hours Released: August 1, 2020 Expired: No longer available for credit

Calli Cook, DNP, APRN, FNP-C, FAANP and Lisa Aquillano, PharmD, BCPS, MSCS: updated McDonald diagnostic and differential diagnosis criteria, MS phenotypes, and MS signs and symptoms.

person default Lisa Aquillano, PharmD, BCPS, MSCS person default Calli Cook, DNP, APRN, FNP-C, FAANP Nurse Practitioners: 0.67 AANP contact hours Released: August 1, 2020 Expired: No longer available for credit
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings